1.Department of ? Innovations thérapeutiques en Oncologie ?, INSERM U563,Institut Claudius Regaud,Toulouse,France;2.Inserm U569, Institut Fédératif de Recherche Louis Bugnard,CHU Rangueil, Chemin du Vallon,Toulouse,France
Abstract:
Background
Polycistronic retroviral vectors that contain several therapeutic genes linked via internal ribosome entry sites (IRES), provide new and effective tools for the co-expression of exogenous cDNAs in clinical gene therapy protocols. For example, tricistronic retroviral vectors could be used to genetically modify antigen presenting cells, enabling them to express different co-stimulatory molecules known to enhance tumor cell immunogenicity.